Meta Information
ID:liposomal-calcium-akg
Name:Liposomal Calcium AKG
Schema Version:1.5
Alternate Names
- Liposomal Ca-AKG
- Liposomal Alpha-Ketoglutarate Calcium Salt
Active Compound
calcium_alpha_ketoglutarate
Intervention Type
therapeutic_agent
Delivery
Route:
oral
Scope:
- systemic
Regulatory Status
- us:dietary_supplement
Indication
Focus:
healthspan
Description:
Aims to support cellular metabolism and potentially slow age-related decline by replenishing alpha-ketoglutarate levels, which decrease with age.
Typical Protocol
- Typical daily doses range from 300 mg to 500 mg, taken with or without food, reflecting the enhanced bioavailability of the liposomal form.
Expected Cost Mean
Low Cost:
60
High Cost:
120
Cost Type:
monthly
Description:
Premium pricing for the liposomal formulation; not covered by insurance.
Summary
Liposomal Calcium AKG is a formulation designed to enhance the bioavailability of alpha-ketoglutarate (AKG), a key metabolite in the Krebs cycle that declines with age. By replenishing AKG, it may support cellular energy production, inhibit mTOR, and promote metabolic health, processes linked to longevity in animal models. The liposomal encapsulation aims to protect the compound from gastric degradation and improve absorption.
Purpose
Replenish a key metabolite to support cellular energy and healthspan.
Card Summary
A bioavailable form of a key metabolic compound that has extended lifespan in animal studies, but human evidence for healthspan is still emerging.
Drug Class
Drugs In Class
Empty Array
Impact
Score:
3.5
Justification:
Promising animal data on lifespan extension, but lacks robust human trial evidence for healthspan.
Evidence
Grade:
C
Score:
3.8
Justification:
Strong mouse lifespan studies exist, but human evidence is limited to preliminary, non-placebo-controlled trials.
Safety
Score:
2.5
Justification:
Generally recognized as safe (GRAS), with minimal side effects at standard doses.
Flags
- Liposomal delivery may significantly alter absorption rates compared to standard Ca-AKG.
- Individuals with kidney disease or hypercalcemia should consult a physician before use.
- Long-term human safety data for healthspan applications is not yet available.
Verdict
A promising but speculative intervention based on strong animal data.
Created
2026-06-12T17:50:24.695267Z
Ai Model
Gemini 2.5 Pro (High)